Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 30060 matches for

A new treatment targeting tenascin-C could reduce the progression and severity of rheumatoid arthritis (RA) at the very early stages of disease.

Meet the team

Read the articles

Targeting early changes in the synovial microenvironment: a new class of immunomodulatory therapy?

Annals of the Rheumatic Diseases 2019;78:186-191.

 

Response to: ‘Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis’ by Cutolo et al

Annals of the Rheumatic Diseases Published Online First: 12 February 2019. doi: 10.1136/annrheumdis-2019-215108

 

Extracellular matrix in the crosshairs, Collison J 

Nature Reviews Rheumatologyvolume 15, page65 (2019) 

Supported by

This work was supported by grants from Nascient Ltd and Versus Arthritis. This work was also supported by the Arthritis Research UK Rheumatoid Arthritis Pathogenesis Centre of Excellence and by the Kennedy Trust for Rheumatology Research. This report includes independent research supported by the National Institute for Health Research/Wellcome Trust Clinical Research Facility at University Hospitals Birmingham NHS Foundation Trust.

Find out more about

Our Groups, Centres and Units

Our Research Themes

Our Clinical Trials

Our Programme Grants

Similar stories